2026-04-20T02:43:53Zhttps://riubu.ubu.es/oai/requestoai:riubu.ubu.es:10259/87972024-03-14T11:52:07Zcom_10259_4219com_10259_5086com_10259_2604col_10259_4220
2024-03-11T11:15:23Z
urn:hdl:10259/8797
Application of the ‘5-2-1’ screening criteria in advanced Parkinson’s disease: interim analysis of DUOGLOBE
Aldred, Jason
Anca-Herschkovitsch, Marieta
Antonini, Angelo
Bajenaru, Ovidiu
Bourgeois, Paul
Cubo Delgado, Esther
Davis, Thomas L.
Iansek, Robert
Kovács, Norbert
Kukreja, Pavnit
Onuk, Koray
Pontieri, Francesco E.
Robieson, Weining
Siddiqui, Mustafa S.
Simu, Mihaela
Standaert, David G.
Chaudhuri, K. Ray
5-2-1
Criteria for advanced PD
Dyskinesia
LCIG
Levodopa
Levodopa-carbidopa intestinal gel
Off time
Parkinson’s disease
Aim: A Delphi expert consensus panel proposed that fulfilling ≥1 of the ‘5-2-1 criteria’ (≥five-times daily oral levodopa use, ≥two daily hours with ‘Off’ symptoms or ≥one daily hour with troublesome dyskinesia) suggests advanced Parkinson’s disease (PD). Patients & methods: DUOdopa/Duopa in Patients with Advanced PD – a GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE) – is a single-arm, postmarketing, observational, long-term effectiveness study of levodopa–carbidopa intestinal gel (LCIG) for advanced PD. Results: This 6-month interim analysis (n = 139) affirms that most (98%) enrolled patients fulfill ≥1 of the 5-2-1 criteria. These patients responded favorably to LCIG treatment. Safety was consistent with other LCIG studies. Conclusion: In advanced PD patients, the 5-2-1 criteria generally aligns with clinician assessment.
2024-03-11T11:15:23Z
2024-03-11T11:15:23Z
2020-09
info:eu-repo/semantics/article
1758-2024
http://hdl.handle.net/10259/8797
10.2217/nmt-2020-0021
1758-2032
eng
Neurodegenerative Disease Management. 2020, V. 10, n. 5, p. 309-323
https://doi.org/10.2217/nmt-2020-0021
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Future Medicine